Lymphoma

An off-the-shelf cellular therapy that combines Epstein Barr Virus–Specific T cells and a CD30-targeting chimeric antigen receptor product demonstrated safety and early efficacy in a group of patients with CD30-positive lymphomas.

The 3-year follow-up analysis of 4 treatment groups who received CNS prophylaxis found a decreased incidence of CNS relapse for patients with high-risk diffuse large B-cell lymphoma, although the data were not statistically significant.

The lymphoma expert discussed how adding copanlisib to rituximab improved progression-free survival, while demonstrating a manageable safety profile in patients with relapsed indolent non-Hodgkin lymphoma.

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.

Data from the phase 2 LOTIS-2 clinical trial supported the accelerated approval of loncastuximab tesirine for patients with relapsed or refractory large B-cell lymphoma.

Patients treated in a multicenter trial experienced a median progression-free survival of 13.2 months with pembrolizumab versus 8.3 months in those receiving brentuximab vedotin.

In a phase 1 study of the innate cell engager AFM13, all 4 patients with CD30-positive, relapsed/refractory Hodgkin lymphoma treated with the therapy achieved at least a partial response.

The lymphoma expert discussed how the addition of copanlisib to rituximab may add another treatment option for patients with relapsed indolent B-cell lymphomas.

Even though the safety profile remained tolerable, treatment with lenalidomide plus R-CHOP did not improve progression-free survival compared with placebo plus R-CHOP for patients with activated B-cell-like subtype of DLBCL.

Data that led to the approval of umbralisib in patients with indolent non-Hodgkin lymphoma— including follicular lymphoma and marginal zone lymphoma—indicates favorable activity of the therapy versus other available PI3K inhibitors.

In a phase 1 trial, the recommended phase 2 dose of glofitamab resulted in frequent and durable complete responses for patients with follicular lymphoma and transformed diffuse large B-cell lymphoma arising from follicular lymphoma.

Combination chemotherapy treatment followed by individualized PET4-guided therapy allowed some patients with unfavorable Hodgkin lymphoma to forego radiotherapy while maintaining efficacy.

A phase 2 trial of single-agent AFM13, a bispecific tetravalent innate cell engager that binds to CD30, will continue following positive results of a preplanned interim futility analysis.

Data in The Lancet Oncology confirmed the standard of care as the optimal dosage to treat patients with indolent non-Hodgkin lymphoma.

Data from the phase 2 ZUMA-5 trial supported the approval of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with follicular lymphoma in the third-line setting.

CancerNetwork® was joined by 2 clinicians from Moffitt Cancer Center to discuss why some patients do not respond to CAR T-cell therapy, despite the significant promise of the treatment modality.

Findings presented at the 2021 Transplant & Cellular Therapy Meetings indicate that patients with B-cell non-Hodgkin lymphoma may benefit from a type of natural killer immunotherapy added to chemotherapy and transplant.

A CASI press release detailed data from a phase 1/2a study examining BI-1206 in combination with rituximab to treat patients with non-Hodgkin lymphoma.

Guidelines released by the Society for Immunotherapy of Cancer are intended to provide clinicians with the most current thinking on how experts can integrate immunotherapy into the treatment of patients with lymphoma.

The approval of umbralisib was primarily based on data from the marginal zone lymphoma and follicular lymphoma patient cohorts of the phase 2b UNITY-NHL trial.

Lisocabtagene maraleucel receives FDA approval for its first indication in patients with large B-cell lymphoma.

“MRD status after both induction therapy and consolidation therapy showed prognostic value. This may provide information for deciding timing of MRD assessment,” wrote the study investigators.

Following phase 2 success, the FDA provided Bioniz Therapeutics with guidance for the design of a phase 3 trial of BNZ-1 in patients with relapsed or refractory cutaneous T-cell lymphoma.

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Investigators on the BRUIN trial reported impressive response rates across multiple B-cell malignancies with the use of the Bruton tyrosine kinase inhibitor LOXO-305, especially in those with heavily pretreated mantle cell lymphoma.

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.